To include your compound in the COVID-19 Resource Center, submit it here.

EntreMed reports Panzem data

EntreMed (NASDAQ:ENMD) said interim data in 29 evaluable patients who received Panzem NCD

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE